Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NHS7108 in Exocrine Pancreatic Insufficiency (EPIC)
NCT07559175Phase 2Recruiting
- Sponsor
- Nestlé Health Science
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 7
01
Overview
A Phase 2 trial of CDX-7108 in exocrine pancreatic insufficiency (EPI), sponsored by Nestlé Health Science. Started Oct 2026; status: recruiting.
02
Drugs
CDX-7108
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT07559175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559175.